VHL and nonpapillary renal cell carcinoma: As a very distinctive feature of ccRCC, a driving mutation or epigenetic silencing of the tumor suppressor gene von Hippel–Lindau (VHL; ∼80–90% of the patients) leads to vascular endothelial growth factor (VEGF) release and increased angiogenesis (10–12).